Second Genome is a clinical stage pharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary drug discovery platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs.
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating computational science, machine learning with human disease biology to redefine diseases, and generate libraries of compounds that are screened in traditional drug discovery and development assays.
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical studies in 2020.